TL8-506是一种特异性TLR8激动剂，具有免疫调节功能，适用于结核病及癌症免疫治疗研究。

/

-25~-15℃避光保存，有效期3年。

[1] Tang J, Sun M, Shi G, Xu Y, Han Y, Li X, Dong W, Zhan L, Qin C. Toll-Like Receptor 8 Agonist Strengthens the Protective Efficacy of ESAT-6 Immunization to Mycobacterium tuberculosis Infection. Front Immunol. 2018 Jan 24;8:1972. doi: 10.3389/fimmu.2017.01972. PMID: 29416532; PMCID: PMC5787779.[2]He M, Soni B, Schwalie PC, Hüsser T, Waltzinger C, De Silva D, Prinz Y, Krümpelmann L, Calabro S, Matos I, Trumpfheller C, Bacac M, Umaña P, Levesque MP, Dummer R, van den Broek M, Gasser S. Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells. J Immunother Cancer. 2022 Jun;10(6):e004268. doi: 10.1136/jitc-2021-004268. PMID: 35688559; PMCID: PMC9189853.